Status:
ACTIVE_NOT_RECRUITING
Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies
Lead Sponsor:
University Hospital, Caen
Conditions:
Chronic B-cell Malignancies
BTK Inhibitors
Eligibility:
All Genders
18+ years
Brief Summary
Background. Ibrutinib and acalabrutinib are both associated with an increased risk of atrial fibrillation (AF) but AF comparative risk between these 2 BTK inhibitors (BTKis) remains largely unknown. ...
Eligibility Criteria
Inclusion
- adult patients
- diagnose with chronic B-cell malignancies using ICD-10-CM codes C91 (lymphoid leukemia), C88.0 (Waldenström macroglobulinemia), C83.1 (mantle cell lymphoma), C81-C96 (malignant neoplasms of lymphoid, hematopoietic and related tissue) or C95 (leukemia of unspecified cell type)
- expose to ibrutinib or acalabrutinib determined by the Anatomical Therapeutic Chemical codes
Exclusion
- \-
Key Trial Info
Start Date :
July 25 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 30 2024
Estimated Enrollment :
15000 Patients enrolled
Trial Details
Trial ID
NCT06561243
Start Date
July 25 2024
End Date
October 30 2024
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Caen University Hospital, Department of Pharmacology
Caen, Normandy, France